Remission and treatment persistence during sequential therapy in rheumatoid arthritis: results from the Estonian Biologic Treatment Registry

Katrin Ulst; Sigrid Vorobjov; Karin Laas; Raili Müller

doi:10.1007/s00296-026-06097-1

Remission and treatment persistence during sequential therapy in rheumatoid arthritis: results from the Estonian Biologic Treatment Registry

Rheumatol Int. 2026 Mar 21;46(4):61. doi: 10.1007/s00296-026-06097-1.

Authors

Katrin Ulst^{1

2}, Sigrid Vorobjov^{3

4}, Karin Laas^{3

5}, Raili Müller^{6

7

3}

Affiliations

¹ Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, Tartu, 51014, Estonia. katrin.ulst@kliinikum.ee.
² Tartu University Hospital, Puusepa 8, Tartu, 51014, Estonia. katrin.ulst@kliinikum.ee.
³ Estonian Society for Rheumatology, Pärnu mnt 104, Tallinn, 11312, Estonia.
⁴ National Institute for Health Development, Paldiski Road 80, Tallinn, 10617, Estonia.
⁵ East-Tallinn Central Hospital, Ravi Street 18, Tallinn, 10138, Estonia.
⁶ Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, Tartu, 51014, Estonia.
⁷ Tartu University Hospital, Puusepa 8, Tartu, 51014, Estonia.

PMID: 41863650
DOI: 10.1007/s00296-026-06097-1

No abstract available

Keywords: Antirheumatic Agents; Biologic therapy; Registry; Remission; Rheumatoid arthritis; Targeted synthetic DMARD; Treatment Outcome; Treatment persistence.

Grants and funding

AbbVie/AbbVie